Cargando…

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancers. Currently, NSCLC therapy is based on the analysis of specific predictors, whose presence qualifies patients for appropriate treatment. Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), also known as “survivin”,...

Descripción completa

Detalles Bibliográficos
Autores principales: Szczyrek, Michał, Mlak, Radosław, Szudy-Szczyrek, Aneta, Wojas-Krawczyk, Kamila, Kędziora, Karolina, Milanowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946487/
https://www.ncbi.nlm.nih.gov/pubmed/35326407
http://dx.doi.org/10.3390/cells11060956
_version_ 1784674204995551232
author Szczyrek, Michał
Mlak, Radosław
Szudy-Szczyrek, Aneta
Wojas-Krawczyk, Kamila
Kędziora, Karolina
Milanowski, Janusz
author_facet Szczyrek, Michał
Mlak, Radosław
Szudy-Szczyrek, Aneta
Wojas-Krawczyk, Kamila
Kędziora, Karolina
Milanowski, Janusz
author_sort Szczyrek, Michał
collection PubMed
description Non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancers. Currently, NSCLC therapy is based on the analysis of specific predictors, whose presence qualifies patients for appropriate treatment. Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), also known as “survivin”, is a protein whose expression is characteristic for most malignant tumors and fetal tissue, while absent in mature cells. The biological role of BIRC5 is to counteract apoptosis by inhibiting the initiating and effector activities of caspases and binding to microtubules of the mitotic spindle. In our study, we looked for a relationship between BIRC5 gene polymorphism and the effectiveness of platinum-based chemotherapy. The study group consisted of 104 patients with newly diagnosed locally advanced or metastatic NSCLC. DNA was isolated from pretreatment blood samples, and SNPs of BIRC5 gene were analyzed. All patients received first-line platinum-based chemotherapy. Univariate analysis showed that a specific BIRC5 genotype was significantly associated with a higher risk of early progression (homozygous GG vs. heterozygous CG or CC: 28.9% vs. 11.9%). The presence of a homozygous GG genotype of the BIRC5 gene was insignificantly related to PFS shortening and TTP shortening. Moreover, significantly higher risk of overall survival shortening was associated with the BIRC5 homozygous GG genotype. Thus, studies on polymorphisms of selected genes affecting apoptosis may have a practical benefit for clinicians who monitor and treat NSCLC.
format Online
Article
Text
id pubmed-8946487
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89464872022-03-25 Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer Szczyrek, Michał Mlak, Radosław Szudy-Szczyrek, Aneta Wojas-Krawczyk, Kamila Kędziora, Karolina Milanowski, Janusz Cells Article Non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancers. Currently, NSCLC therapy is based on the analysis of specific predictors, whose presence qualifies patients for appropriate treatment. Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), also known as “survivin”, is a protein whose expression is characteristic for most malignant tumors and fetal tissue, while absent in mature cells. The biological role of BIRC5 is to counteract apoptosis by inhibiting the initiating and effector activities of caspases and binding to microtubules of the mitotic spindle. In our study, we looked for a relationship between BIRC5 gene polymorphism and the effectiveness of platinum-based chemotherapy. The study group consisted of 104 patients with newly diagnosed locally advanced or metastatic NSCLC. DNA was isolated from pretreatment blood samples, and SNPs of BIRC5 gene were analyzed. All patients received first-line platinum-based chemotherapy. Univariate analysis showed that a specific BIRC5 genotype was significantly associated with a higher risk of early progression (homozygous GG vs. heterozygous CG or CC: 28.9% vs. 11.9%). The presence of a homozygous GG genotype of the BIRC5 gene was insignificantly related to PFS shortening and TTP shortening. Moreover, significantly higher risk of overall survival shortening was associated with the BIRC5 homozygous GG genotype. Thus, studies on polymorphisms of selected genes affecting apoptosis may have a practical benefit for clinicians who monitor and treat NSCLC. MDPI 2022-03-10 /pmc/articles/PMC8946487/ /pubmed/35326407 http://dx.doi.org/10.3390/cells11060956 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Szczyrek, Michał
Mlak, Radosław
Szudy-Szczyrek, Aneta
Wojas-Krawczyk, Kamila
Kędziora, Karolina
Milanowski, Janusz
Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
title Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
title_full Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
title_fullStr Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
title_full_unstemmed Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
title_short Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
title_sort polymorphism of baculoviral inhibitor of apoptosis repeat-containing 5 (birc5) can be associated with clinical outcome of non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946487/
https://www.ncbi.nlm.nih.gov/pubmed/35326407
http://dx.doi.org/10.3390/cells11060956
work_keys_str_mv AT szczyrekmichał polymorphismofbaculoviralinhibitorofapoptosisrepeatcontaining5birc5canbeassociatedwithclinicaloutcomeofnonsmallcelllungcancer
AT mlakradosław polymorphismofbaculoviralinhibitorofapoptosisrepeatcontaining5birc5canbeassociatedwithclinicaloutcomeofnonsmallcelllungcancer
AT szudyszczyrekaneta polymorphismofbaculoviralinhibitorofapoptosisrepeatcontaining5birc5canbeassociatedwithclinicaloutcomeofnonsmallcelllungcancer
AT wojaskrawczykkamila polymorphismofbaculoviralinhibitorofapoptosisrepeatcontaining5birc5canbeassociatedwithclinicaloutcomeofnonsmallcelllungcancer
AT kedziorakarolina polymorphismofbaculoviralinhibitorofapoptosisrepeatcontaining5birc5canbeassociatedwithclinicaloutcomeofnonsmallcelllungcancer
AT milanowskijanusz polymorphismofbaculoviralinhibitorofapoptosisrepeatcontaining5birc5canbeassociatedwithclinicaloutcomeofnonsmallcelllungcancer